Cellenion and Miltenyi Biotec Sign Co-Marketing Agreement to Provide a Time and Cost-Efficient Solution for the Development of Monoclonal Cell Lines
Scienion AG and Miltenyi Biotec GmbH today announced that Scienion’s affiliate Cellenion and Miltenyi Biotec have signed a co-marketing agreement to considerably improve and accelerate the development of monoclonal cell lines by combined use of their state-of-the-art cell sorter and single cell dispenser devices.
The introduction of biologicals such as antibodies or other proteins has led to significant improvements in medicine and continues to show a rapidly growing impact on targeted therapies in various indications. Monoclonal cell lines build the basis for the production of biologicals. However, creating high-expressing cell lines remains to be a complex and time-consuming process.
Successful collaborative research efforts by Cellenion and Miltenyi Biotec have shown how to efficiently improve and accelerate this process by the combined use of Miltenyi Biotec’s MACSQuant® Tyto® Cell Sorter and Cellenion’s cellenONE® X1 single-cell deposition unit and thus provide a solution for this challenge. The results of these studies were published in a joint Application Note which was presented for the first time at the BioProcess International European Summit 2018 in Amsterdam, April 23-25.
Bastian Ackermann, Global Product Manager MACSQuant Tyto at Miltenyi Biotech, stated: “We have been using cellenONE in combination with our latest cell sorter, the MACSQuant Tyto. These two technologies offer a great combination for cell line development. The MACSQuant Tyto Sorter is an easy to operate instrument that gently enriches the cell population of interest, while cellenONE’s accuracy allows for highly efficient clone selection from the enriched population. Used together, these two technologies reduced our monoclonal antibody development protocols by nearly four weeks.”
Guilhem Tourniaire, Managing Director of Cellenion SASU, further commented: “Our cellenONE X1 allows for unique optically monitored single cell isolation and thus outpaces any manual methods for this purpose. Combining cell sorting with MACSQuant Tyto and cloning with cellenONE X1 provides superior benefits for advanced cell line development: Beside their accuracy, both systems handle cells very gently which results in high cell viability. Furthermore, both systems are fully automated and thereby facilitate laboratory routine.”
Proof-of-principle studies were performed with a suspension of HEK293T wild type cells and stably transduced HEK293T cells expressing a fluorescent agent (GFP, green fluorescent protein). HEK293T is a cell line derived from human embryonic kidney cells which is commonly used to produce therapeutic proteins. The study design focused on a comparison between manual cloning, automated cloning by cellenONE X1 and automated sorting by MACSQuant Tyto with subsequent cloning by cellenONE X1. Results clearly demonstrated the power of combining the use of MACSQuant Tyto and cellenONE X1 with respect to efficiency, time, simplicity of operation and cost-savings.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company’s innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Miltenyi Biotec’s technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, preclinical imaging and cell manufacturing. Their almost 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, apheresis and cell and gene therapy. In their commitment to the scientific community, Miltenyi Biotec also offers comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 2,000 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.
SCIENION offers complete solutions for precise liquid dispensing applications enabling high throughput production of multiparameter assays in diagnostics, and life and material sciences. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, SCIENION offers a unique technology portfolio that has been continuously expanded for over 15 years. SCIENION provides flexible solutions for research and development, wherein solutions for production purposes are customized. Systems and software are characterized by their versatility, precision and robustness. The company is a renowned specialist for ultra-low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. SCIENION’s dispensers allow for contact-free and precise drop spotting in the pico- to micro-liter range and are optimally suited for microarray based analytics – such as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various substrates. The company operates from two sites in Germany, Dortmund and Berlin, and has subsidiaries in Arizona and New Jersey in USA, and Lyon in France.
Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of bioprinting and single-cell isolation. Cellenion has developed cellenONE®, a unique single-cell isolation and dispensing technology. It allows high throughput automated dispensing of individual cells from cell suspensions onto any substrates of choice. The company has also developed a proprietary high throughput formulation and screening platform for the development and optimization of bio-inks. Cellenion operates from Lyon, France. The company is a subsidiary of Scienion AG (www.scienion.com) and its cellenONE single cell dispenser is exclusively sold by SCIENION worldwide.
Miltenyi Biotec GmbH
51429 Bergisch Gladbach
Phone: +49 2204 8306 5438
Phone +49 (0)30 - 6392 1700
Fax: +49 (0)30 - 6392 1701
Dr. Guilhem Tourniaire
60 Avenue Rockefeller
Phone: +33 (0)9 86 48 70 70